Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Rabuka

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Molecular Cancer Therapeutics|November 17, 2017
CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDR1-Resistant Maytansine Payload Yields Excellent Efficacy and Safety in Preclinical ModelsPenelope M Drake, Adam Carlson, Jesse M McFarland, et al.
Molecular Cancer Therapeutics|July 12, 2020
A Novel HER2-targeted Antibody-drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure LevelsRobyn M Barfield, Yun Cheol Kim, Stepan Chuprakov, et al.
Nature Chemical Biology|August 28, 2019
CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicityC Kimberly Tsui, Robyn M Barfield, Curt R Fischer, et al.
Chemistry & Biology|January 27, 2015
Generating site-specifically modified proteins via a versatile and stable nucleophilic carbon ligationRomas Kudirka, Robyn M Barfield, Jesse McFarland, et al.
Journal of the American Chemical Society|July 6, 2017
Rapid Characterization of a Mechanically Labile α-Helical Protein Enabled by Efficient Site-Specific BioconjugationRobert Walder, Marc-André LeBlanc, William J Van Patten, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2004
Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agentsSulan Yao, Paulo W M Sgarbi, Kenneth A Marby, et al.
Antibodies (Basel, Switzerland)|November 8, 2019
Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast CancerEfrat T Harel, Penelope M Drake, Robyn M Barfield, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2005
Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activitiesChang-Hsing Liang, Alex Romero, David Rabuka, et al.
Bioconjugate Chemistry|June 14, 2014
Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomesPenelope M Drake, Aaron E Albers, Jeanne Baker, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Molecular Cancer Therapeutics|November 17, 2017
CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDR1-Resistant Maytansine Payload Yields Excellent Efficacy and Safety in Preclinical ModelsPenelope M Drake, Adam Carlson, Jesse M McFarland, et al.
Molecular Cancer Therapeutics|July 12, 2020
A Novel HER2-targeted Antibody-drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure LevelsRobyn M Barfield, Yun Cheol Kim, Stepan Chuprakov, et al.
Nature Chemical Biology|August 28, 2019
CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicityC Kimberly Tsui, Robyn M Barfield, Curt R Fischer, et al.
Chemistry & Biology|January 27, 2015
Generating site-specifically modified proteins via a versatile and stable nucleophilic carbon ligationRomas Kudirka, Robyn M Barfield, Jesse McFarland, et al.
Journal of the American Chemical Society|July 6, 2017
Rapid Characterization of a Mechanically Labile α-Helical Protein Enabled by Efficient Site-Specific BioconjugationRobert Walder, Marc-André LeBlanc, William J Van Patten, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2004
Glyco-optimization of aminoglycosides: new aminoglycosides as novel anti-infective agentsSulan Yao, Paulo W M Sgarbi, Kenneth A Marby, et al.
Antibodies (Basel, Switzerland)|November 8, 2019
Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast CancerEfrat T Harel, Penelope M Drake, Robyn M Barfield, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2005
Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activitiesChang-Hsing Liang, Alex Romero, David Rabuka, et al.
Bioconjugate Chemistry|June 14, 2014
Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomesPenelope M Drake, Aaron E Albers, Jeanne Baker, et al.
Pageof 5